NL-OMON34689已完成不适用
The value of biomarkers in cerebrospinal fluid in acute spinal cord injury as predictor of outcome. - SPinal cord Diagnostic Improvements (SPIDI) study
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Blunt spinal cord injury (Neurological level of injury C2-Th10)
- •Neurological deficit
- •Primarily refererred
- •Glasgow Coma Scale >= 10 (E4+V6)
排除标准
- •penetrating spinal cord injury
- •normal neurologic examination
- •non-traumatic spinal cord injury
- •traumatic brain injury
- •pre-existent neurological disorder
研究者
相似试验
尚未招募
不适用
Cerebrospinal fluid metabolites as marker for the severity of progressive post-hemorrhagic ventricular dilatation in preterm infantsNL-OMON30135niversitair Medisch Centrum Sint Radboud125
已完成
不适用
Identification of Biomarkers in Spinocerebellar Ataxia 3Spinocerebellar Ataxia Type 3NCT03885167University of Michigan22
招募中
不适用
Identification of a CSF- and blood biomarker fingerprint differentiating between highly active and moderate/mild forms of multiple sclerosis (MS)Multiple sclerosisG35DRKS00015761Klinikum der Johann Wolfgang Goethe-UniversitätZentrum der Neurologie und Neurochirurgie200
尚未招募
不适用
Hersenvocht bij psychiatrische aandoeningePsychosis, schizophrenia, affective disorders, depressionNL-OMON26758niversity Medical Center Utrecht800
进行中（未招募）
2 期
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy ExtensionGaucher Disease Type 1Gaucher Disease Type 3NCT02843035Genzyme, a Sanofi Company12